Despite advancement in treatment for childhood central nervous system (CNS) tumors, they remain the leading cause of death in pediatric oncology. One potential therapeutic intervention is targeting the autophagic pathway, a complex catabolic process that contributes to tumor cell survival. Recent data has shown BRAFV600E mutations in a range of these tumors and my own research finds that these tumors show autophagy-dependence not seen in BRAFWT tumors. There is also evidence that autophagy inhibition is a potential mechanism in preventing or reversing resistance to direct inhibition against activated BRAFV600E. The proposed study will examine the interaction of the BRAFV600E mutation and autophagy in brain tumors. I hypothesize that BRAFV600E identifies tumors that will respond to combination therapy with autophagy inhibition with enhanced tumor cell death, establishing a basis for future rational clinical trial design for pediatric brain tumo patients harboring the mutation.
Aim 1 will determine how the BRAFV600E mutation results in sensitization of CNS tumor cells to autophagy inhibition by evaluating ERK activity using isogenic BRAF models.
Aim 2 will evaluate the effectiveness of autophagy inhibition to improve chemosensitivity in BRAF mutant CNS tumors ex vivo and in vivo. Combination therapy with chloroquine (autophagy inhibition) and vemurafenib (Raf-inhibitor) will be assessed in orthotopic murine models as well as organotypic slice cultures.
Aim 3 will evaluate the effectiveness of autophagy inhibition as a therapeutic strategy to overcome acquired small molecule inhibition of oncogenic BRAF in pediatric brain tumors and the role of PUMA and apoptosis in mediating these effects. A combination of in vitro, ex vivo and in vivo methods will be utilized to achieve the stated Aims and clarify the role of BRAFV600E and autophagy in pediatric CNS tumors. Autophagy will be studied using the latest methods including flow cytometry and fluorescent microscopy. Detailed analysis of the MAP kinase pathways will be included. Isogenic cell lines will be used to remove other confounding genetic interactions. Intracranial mouse tumor models and organotypic slice cultures will be used to validate in vitro findings. In vivo studies have bee designed to simulate clinical treatment as best as possible to provided pre-clinical data for clinical trial proposals. Understanding these differences is vital to identifying patients who will most likely benefit from autophagy inhibition as an added therapy, allowing patients who will not benefit to focus their treatment efforts on more potentially beneficial efforts. Data obtained from these studies will be influential in the design of future clinical trials specifically devised to optimize the manipulation of autophagy with the intent of improving the care and survival of pediatric brain tumor patients.

Public Health Relevance

The proposed study will expand our understanding of the role of autophagy (meaning self-eating in Greek) in the treatment of children with brain tumors harboring BRAF mutations. Completion of this study has high potential to impact the treatment of pediatric patients with brain tumors and in the design of future clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA193982-04
Application #
9535241
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lim, Susan E
Project Start
2015-09-23
Project End
2020-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Pediatrics
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Witt, Davis A; Donson, Andrew M; Amani, Vladimir et al. (2018) Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer 65:e26960
Nellan, Anandani; Rota, Christopher; Majzner, Robbie et al. (2018) Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer 6:30
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Grob, Sydney T; Levy, Jean M Mulcahy (2018) Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors. Mol Diagn Ther 22:25-39
Griesinger, Andrea M; Witt, Davis A; Grob, Sydney T et al. (2017) NF-?B upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma. Neuro Oncol 19:1350-1360
Dahl, Nathan A; Luebbert, Timothy; Loi, Michele et al. (2017) Chordoma Occurs in Young Children With Tuberous Sclerosis. J Neuropathol Exp Neurol 76:418-423
Levy, Jean M Mulcahy; Towers, Christina G; Thorburn, Andrew (2017) Targeting autophagy in cancer. Nat Rev Cancer 17:528-542
Mulcahy Levy, Jean M; Zahedi, Shadi; Griesinger, Andrea M et al. (2017) Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. Elife 6:
Lassaletta, Alvaro; Zapotocky, Michal; Mistry, Matthew et al. (2017) Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. J Clin Oncol 35:2934-2941
Klionsky, Daniel J (see original citation for additional authors) (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1-222

Showing the most recent 10 out of 11 publications